Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; maize starch; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; methacrylic acid copolymer; triethyl citrate; purified talc; titanium dioxide; iron oxide yellow - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: triethyl citrate; purified talc; sodium starch glycollate; magnesium stearate; maize starch; iron oxide yellow; calcium hydrogen phosphate dihydrate; methacrylic acid copolymer; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; lactose monohydrate - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; maize starch; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; methacrylic acid copolymer; triethyl citrate; purified talc; titanium dioxide; iron oxide yellow - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; iron oxide yellow; purified talc; titanium dioxide; calcium hydrogen phosphate dihydrate; maize starch; colloidal anhydrous silica; magnesium stearate; triethyl citrate; methacrylic acid copolymer - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: sodium starch glycollate type a; iron oxide yellow; povidone; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; microcrystalline cellulose; titanium dioxide; purified talc; magnesium stearate; hypromellose; lactose monohydrate; triethyl citrate; peg-40 hydrogenated castor oil; colloidal anhydrous silica - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: macrogol 8000; iron oxide yellow; peg-40 hydrogenated castor oil; acrylates copolymer; maize starch; sodium starch glycollate; purified talc; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; magnesium stearate; povidone; lactose monohydrate; titanium dioxide; simethicone; sorbic acid; steareth-2 - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; iron oxide yellow; purified talc; peg-40 hydrogenated castor oil; methacrylic acid - ethyl acrylate copolymer (1:1); lactose monohydrate; maize starch; triethyl citrate; povidone; hypromellose; titanium dioxide - inflammatory and degenerative forms of rheumatism: rheumatoid arthritis and osteoarthritis. relief of acute or chronic pain states in which there is an,inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: maize starch; methacrylic acid copolymer; colloidal anhydrous silica; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; purified talc; triethyl citrate; iron oxide yellow; titanium dioxide; lactose monohydrate; sodium starch glycollate - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: methacrylic acid copolymer; magnesium stearate; microcrystalline cellulose; triethyl citrate; purified talc; maize starch; colloidal anhydrous silica; sodium starch glycollate; titanium dioxide; iron oxide yellow; lactose monohydrate; calcium hydrogen phosphate dihydrate - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

United States - English - NLM (National Library of Medicine)

sircle laboratories, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 16.05 mg in 1 ml - diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (nsaid) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). diclofenac sodium topical solution is contraindicated in patients with a known hypersensitivity to diclofenac sodium or any other component of diclofenac sodium topical solution. diclofenac sodium topical solution is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.10)]. diclofenac sodium topical solution is contraindicated in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1)]. pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. teratogenic effects: there are no adequate and well-controlled studies of diclofenac sodium topical solution in pregnant w